Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Johnson & Johnson (JNJ) today and set a price target of $190.00. The company’s shares closed last Tuesday at $170.48, close to its 52-week high of $173.65.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of 21.6% and a 71.9% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Merit Medical Systems.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Johnson & Johnson with a $191.00 average price target, which is a 12.6% upside from current levels. In a report released yesterday, Raymond James also assigned a Buy rating to the stock with a $183.00 price target.
See today’s analyst top recommended stocks >>
Johnson & Johnson’s market cap is currently $448.8B and has a P/E ratio of 26.10. The company has a Price to Book ratio of -25.95.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Read More on JNJ:
